S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Arcus Biosciences (RCUS) Stock Forecast, Price & News

+0.42 (+2.27%)
(As of 05/20/2022 06:40 PM ET)
Today's Range
50-Day Range
52-Week Range
1.04 million shs
Average Volume
1.09 million shs
Market Capitalization
$1.36 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Arcus Biosciences logo

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$382.88 million
Cash Flow
$0.89 per share
Book Value
$11.11 per share


Net Income
$52.83 million
Pretax Margin




Free Float
Market Cap
$1.36 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.25 out of 5 stars

Medical Sector

321st out of 1,416 stocks

Pharmaceutical Preparations Industry

123rd out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 8,460,000 shares, an increase of 48.2% from the March 31st total of 5,710,000 shares. Based on an average trading volume of 991,900 shares, the short-interest ratio is currently 8.5 days. Currently, 19.0% of the company's stock are short sold.
View Arcus Biosciences' Short Interest

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arcus Biosciences

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of $0.83 by $1.79. Arcus Biosciences had a trailing twelve-month return on equity of 8.25% and a net margin of 14.67%. During the same quarter in the previous year, the business posted ($1.08) earnings per share.
View Arcus Biosciences' earnings history

What price target have analysts set for RCUS?

6 Wall Street analysts have issued 1-year target prices for Arcus Biosciences' stock. Their forecasts range from $42.00 to $100.00. On average, they expect Arcus Biosciences' stock price to reach $60.86 in the next twelve months. This suggests a possible upside of 221.7% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the following people:
  • Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 62, Pay $932.12k)
  • Dr. Juan Carlos Jaen Ph.D., Co-Founder, Pres & Director (Age 64, Pay $838.2k)
  • Mr. Robert C. Goeltz II, Principal Financial & Accounting Officer and CFO (Age 49, Pay $613.2k) (LinkedIn Profile)
  • Ms. Jennifer Jarrett M.B.A., COO & Director (Age 51, Pay $828.2k) (LinkedIn Profile)
  • Ms. Carolyn C. Tang J.D., Gen. Counsel & Corp. Sec. (Age 43, Pay $603.2k) (LinkedIn Profile)
  • Dr. Stephen Young Ph.D., Sr. VP of Technology & Quantitative Biology (Age 53)
  • Dr. Jonathan Yingling Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Katherine Bock, VP of Investor Relations & Corp. Strategy
  • Holli Kolkey, VP of Corp. Communications
  • Ms. Yvonne Gehring, VP of HR & Operations
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.77%), Vanguard Group Inc. (4.90%), State Street Corp (3.83%), Decheng Capital Management III Cayman LLC (1.21%), TimesSquare Capital Management LLC (1.15%) and Northern Trust Corp (0.84%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, TimesSquare Capital Management LLC, First Trust Advisors LP, Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Northern Trust Corp, Federated Hermes Inc., and Metropolitan Life Insurance Co NY. Company insiders that have sold Arcus Biosciences company stock in the last year include Carolyn C Tang, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences
or view top insider-selling stocks.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, State Street Corp, Dimensional Fund Advisors LP, UBS Group AG, Sessa Capital IM L.P., Goldman Sachs Group Inc., Invesco Ltd., and Granahan Investment Management LLC. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $18.92.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $1.36 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.549990 on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 366 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at (510) 694-6200 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.